|
Efficacy of Cefoperazone/Sulbactam combined with Tanreqing injection inelderly patients with nosocomial Pseudomonas aeruginosa pneumonia |
Received:December 04, 2020 |
View Full Text View/Add Comment Download reader |
DOI:10.11915/j.issn.1671-5403.2021.09.143 |
Key words:Pseudomonas aeruginosa Tanyanqing injection Cefoperazone/Sulbactam efficacy pneumonia Corresponding author:YANG Yuan, E-mail:yyong653@163.com〖FL |
|
Hits: 204 |
Download times: 180 |
Abstract: |
Objective To explore the efficacy of Cefoperazone/Sulbactam combined with Tanreqing injection in the elderly patients with the nosocomial Pseudomonas aeruginosa (PA) pneumonia. Methods A total of 80 elderly patients were selected for the study, who developed PA pneumonia after 48 hours of hospitalization in the Second Department of Internal Medicine, Henan Provincial Armed Police Corps Hospital from June 1,2016 to November 30,2020. They were divided into Supushen group (cefoperazone/sulbactam, n=25), Tanreqing group (n=20), and Tanreqing + Shupushen group (n=35). The three groups were compared in the clinical efficacy, fever degree, sputum secretion, neutrophils (NE), white blood cells (WBC), procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 ( IL-6) level. SPSS statistics 20.0 was used for statistical analysis. Depending on date type, comparison between the groups was performed using χ2 test or t test. Results PA was identified in 95.00% (285/300) of the sputum specimens obtained in the 80 patients, and in vitro drug sensitivity test showed that the selection of cefoperazone and sulbactam was the most reasonable. The effectiveness in the Shupushen group was 92.00% (23/25), significantly higher than 85.00% (17/20) in the Tanreqing group but lower than 97.20% (34/35) in the Tanreqing + Shupushen group, the difference being statistically significant (all P<0.05). The number of patients with body temperature recovery in the Shupushen group (80.00%, 20/25) was higher than that in the Tanreqing group (70.00%, 14/20) but lower than that in the Tanreqing + Shupushen group (91.43%, 32/35); the number of the patients with sputum secretion <50 ml in the Shupushen group (84.00%, 21/25) was higher than that in the Tanreqing group (75.00%, 15/20) but lower than that in the Tanreqing + Shupushen group (85.71%, 30/35), the differences being statistically significant (all P<0.05). NE, WBC, PCT, CRP and IL-6 in the Tanreqing group was significantly higher than those in the Shupushen group but significantly lower than those in the Shupushen group (all P<0.05). Conclusion Tanreqing injection combined with cefoperazone/sulbactam can effectively relieve pulmonary inflammation and infection caused by PA and is significant in clinical application. |
Close |
|
|
|